Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
Author:
Publisher
Springer Science and Business Media LLC
Subject
Health Informatics,Epidemiology
Link
http://link.springer.com/article/10.1186/1471-2288-13-152/fulltext.html
Reference21 articles.
1. Royston P, Parmar MKB: The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011, 30: 2409-2421. 10.1002/sim.4274.
2. Schemper M, Wakounig S, Heinze G: The estimation of average hazard ratios by weighted Cox regression. Stat Med. 2009, 28: 2473-2489. 10.1002/sim.3623.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009, 361: 947-957. 10.1056/NEJMoa0810699.
4. Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, Carey MS: Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol. 2011, 29 (S): LBA5006-
5. Andersen PK, Perme MP: Pseudo-observations in survival analysis. Stat Methods Med Res. 2010, 19: 71-99. 10.1177/0962280209105020.
Cited by 670 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Persistent Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Rectal Cancer;JAMA Network Open;2024-09-12
2. Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study;Cancer Immunology, Immunotherapy;2024-09-09
3. Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting;Journal of Comparative Effectiveness Research;2024-09
4. Handgrip strength and mortality in a cohort of kidney failure patients: Comparative analysis of different normalization methods;Nutrition;2024-09
5. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab;Journal of Clinical Oncology;2024-08-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3